UnitedHealthcare Prepares for ICD-10

Ready or not, ICD-10 is happening. Implementation of the expanded diagnosis code set may be two years away, but at least one insurer isn’t letting the grass grow under its feet. UnitedHealthcare is hard at work updating its medical and drug policies and coverage determination guidelines with applicable ICD-10 codes in preparation for the transition from ICD-9-CM to ICD-10 medical coding on Oct. 1, 2014.

Here’s a list of UnitedHealthcare policies newly updated for ICD-10:

17-alpha-hydroxyprogesterone caproate (17P and Makena™)

Botulinum Toxins A and B

CAMPATH® (alemtuzumab)

Gender Identity Disorder Treatment (Sex Transformation)

Growth Hormone/Growth Stimulation Products – Somatropin and Mecasermin

Lithotripsy for Salivary Stones

Orencia® (abatacept)

REMICADE® (infliximab)

RITUXAN® (rituximab)

Sandostatin®/Sandostatin Lar® Depot (octreotide acetate)

SYNAGIS® (palivizumab)

TYSABRI® (natalizumab)

XOLAIR® (omalizumab)

Coders can take advantage of these updated policies by noting how they will be coding diagnoses in the very real and very near future.

Latest posts by admin aapc (see all)

Read the complete Article

Login as a member or sign up for free to get uninterrupted access to AAPC blog posts and stay updated on industry news through our monthly newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *